SUNPHARMA

SUN PHARMACEUTICAL INDUSTRIES

Large Cap BSE: 524715 NSE: SUNPHARMA
₹913.45
-7.6 (-0.83%)
As on 14 August, 2022 | 12:09

Sun Pharmaceutical Industries Share Price

Sun Pharmaceutical Industries Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Sun Pharmaceutical Industries Share Returns

  • Over 1 Month 7.26%
  • Over 3 Month 7.46%
  • Over 6 Month 3.79%
  • Over 1 Year 17.31%

Sun Pharmaceutical Industries Key Statistics

P/E Ratio 56.3
PEG Ratio -1.6
Market Cap Cr 219,167
Price to Book Ratio 4.3
EPS -5.6
Dividend 1
Relative Strength Index 58.41
Money Flow Index 65.83
MACD Signal 15.75
Average True Range 19.83

Sun Pharmaceutical Industries Investment Rating

  • Master Rating:
  • Sun Pharm.Industries has an operating revenue of Rs. 39,697.51 Cr. on a trailing 12-month basis. An annual revenue growth of 15% is outstanding, Pre-tax margin of 12% is healthy, ROE of 6% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 6% and 7% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 4% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 31 which is a POOR score indicating inconsistency in earnings, a RS Rating of 57 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 97 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Sun Pharmaceutical Industries Financials
  • Indicator
  • Jun 2022
  • Mar 2022
  • Dec 2021
  • Sep 2021
  • Jun 2021
  • Mar 2021
  • Oper Rev Qtr Cr
  • 4,862
  • 3,988
  • 3,771
  • 4,143
  • 3,313
  • 3,119
  • Operating Expenses Qtr Cr
  • 3,483
  • 3,007
  • 3,114
  • 3,279
  • 2,694
  • 2,479
  • Operating Profit Qtr Cr
  • 1,450
  • 1,000
  • 656
  • 864
  • 631
  • 680
  • Depreciation Qtr Cr
  • 375
  • 354
  • 355
  • 334
  • 151
  • 152
  • Interest Qtr Cr
  • 87
  • 91
  • 85
  • 104
  • 106
  • 103
  • Tax Qtr Cr
  • 25
  • 486
  • 5
  • -98
  • 13
  • 44
  • Net Profit Qtr Cr
  • 1,012
  • -1,286
  • 515
  • 809
  • 419
  • 327

Sun Pharmaceutical Industries Technicals

EMA & SMA

Current Price
913.45
-7.6 (-0.83%)
  • Bullish Moving Average
  • ___
  • 13
  • Bearish Moving Average
  • ___
  • 3
  • 20 Day
  • 898.37
  • 50 Day
  • 880.39
  • 100 Day
  • 870.76
  • 200 Day
  • 852.75
  • 20 Day
  • 897.41
  • 50 Day
  • 861.23
  • 100 Day
  • 882.86
  • 200 Day
  • 852.64

Sun Pharmaceutical Industries Resistance and Support

PIVOT
₹921.8
Resistance
  • First Resistance
  • 926.15
  • Second Resistance
  • 931.25
  • Third Resistance
  • 935.6
Support
  • First Resistance
  • 916.7
  • Second Resistance
  • 912.35
  • Third Resistance
  • 907.25
  • RSI
  • 58.41
  • MFI
  • 65.83
  • MACD Single Line
  • 15.75
  • MACD
  • 16.2

Sun Pharmaceutical Industries Delivery and Volume

  • Period
  • NSE + BSE
    Volume Avg
  • NSE + BSE
    Delivery Volume Avg
  • NSE + BSE
    Delivery Volume %
  • Day
  • 1,412,209
  • 60,484,911
  • 42.83
  • Week
  • 2,255,692
  • 131,191,061
  • 58.16
  • 1 Month
  • 3,275,412
  • 159,872,836
  • 48.81
  • 6 Month
  • 3,226,863
  • 164,763,627
  • 51.06

Sun Pharmaceutical Industries Result Highlights

Sun Pharmaceutical Industries Synopsis

NSE-Medical-Generic Drugs

Sun Pharma. is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 15585.98 Cr. and Equity Capital is Rs. 239.93 Cr. for the Year ended 31/03/2022. Sun Pharmaceutical Industries Ltd. is a Public Limited Listed company incorporated on 01/03/1993 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1993PLC019050 and registration number is 019050.
  • Market Cap
  • 219,167
  • Sales
  • 16,854
  • Shares in Float
  • 110.37
  • No of funds
  • 952
  • Yield
  • 1.09
  • Book Value
  • 8.91
  • U/D Vol ratio
  • 0.9
  • LTDebt / Equity
  • 20
  • Alpha
  • 0.05
  • Beta
  • 0.69

Sun Pharmaceutical Industries

  • Owner Name
  • Jun-22
  • Mar-22
  • Dec-21
  • Sep-21
  • Promoters
  • 54.48%
  • 54.48%
  • 54.48%
  • Mutual Funds
  • 11.84%
  • 11.63%
  • 11.8%
  • Insurance Companies
  • 7.52%
  • 7.94%
  • 8.67%
  • Foreign Portfolio Investors
  • 14.95%
  • 14.44%
  • 13%
  • Financial Institutions/ Banks
  • 0.22%
  • 0.37%
  • 0.47%
  • Individual Investors
  • 6.31%
  • 6.49%
  • 6.69%
  • Others
  • 4.68%
  • 4.65%
  • 4.89%

Sun Pharmaceutical Industries Management

  • Name
  • Designation
  • Mr. Israel Makov
  • Chairman, Non Ind & Non Exe Director
  • Mr. Dilip S Shanghvi
  • Managing Director
  • Mr. Sailesh T Desai
  • Whole Time Director
  • Mr. Kalyanasundaram Subramanian
  • Whole Time Director
  • Mr. Sudhir V Valia
  • Non Exe.Non Ind.Director
  • Dr. Pawan Goenka
  • Non Exe. & Ind. Director
  • Mr. Rama Bijapurkar
  • Non Exe. & Ind. Director
  • Mr. Gautam Doshi
  • Ind. Non-Executive Director

Sun Pharmaceutical Industries Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Sun Pharmaceutical Industries Corporate Action

  • Date
  • Purpose
  • Remarks
  • 2022-07-29
  • Quarterly Results
  • 2022-05-30
  • Audited Results & Final Dividend
  • 2022-01-31
  • Quarterly Results & Interim Dividend
  • 2021-11-02
  • Quarterly Results
  • 2021-07-30
  • Quarterly Results
  • Date
  • Purpose
  • Remarks
  • 2022-08-22
  • FINAL
  • Rs.3.00 per share(300%)Final Dividend
  • 2022-02-10
  • INTERIM
  • Rs.7.00 per share(700%)Interim Dividend
  • 2021-02-10
  • INTERIM
  • Rs.5.50 per share(550%)Interim Dividend

Sun Pharmaceutical Industries MF Shareholding

  • Name
  • Amount(cr)
  • SBI Nifty 50 ETF
  • 135323
  • SBI S&P BSE Sensex ETF
  • 72360
  • SBI Equity Hybrid Fund Regular Payout Inc Dist cum Cap Wdrl
  • 53018
  • HDFC Balanced Advantage Fund Growth
  • 46130
  • ICICI Prudential Balanced Advantage Fund Growth
  • 41742

Sun Pharmaceutical Industries FAQs

What is Share Price of Sun Pharmaceutical Industries ?

Sun Pharmaceutical Industries share price is ₹913 As on 14 August, 2022 | 11:55

What is the Market Cap of Sun Pharmaceutical Industries ?

The Market Cap of Sun Pharmaceutical Industries is ₹219167.3 Cr As on 14 August, 2022 | 11:55

What is the P/E ratio of Sun Pharmaceutical Industries ?

The P/E ratio of Sun Pharmaceutical Industries is 56.3 As on 14 August, 2022 | 11:55

What is the PB ratio of Sun Pharmaceutical Industries ?

The PB ratio of Sun Pharmaceutical Industries is 4.3 As on 14 August, 2022 | 11:55

What is the future of Sun Pharmaceutical Industries (Sun Pharma)?

Sun Pharmaceutical Industries (Sun Pharma) has an operating revenue of INR 36,704.43 Cr. on a trailing 12-month basis. Annual revenue growth of 3% is not great, Pre-tax margin of 8% is okay. Institutional holding has gone up in the last reported quarter is a positive sign. Analyst Recommendation on Sun Pharmaceutical Industries (Sun Pharma): HOLD

Who is the Managing Director of Sun Pharmaceutical Industries (Sun Pharma)?

Dilip Shanghvi is the Managing Director of Sun Pharmaceutical Industries (Sun Pharma).

What is the ROE of Sun Pharmaceutical Industries (Sun Pharma)?

The ROE of Sun Pharmaceutical Industries (Sun Pharma) is 6% which is fair but needs improvement.

Is Sun Pharmaceutical Industries (Sun Pharma) Debt to Equity Ratio?

Sun Pharmaceutical Industries (Sun Pharma) has a reasonable debt to equity of 2%, which signals a healthy balance sheet.

What is the PE ratio of Sun Pharmaceutical Industries (Sun Pharma)?

The PE ratio of Sun Pharmaceutical Industries (Sun Pharma) is 81.5.

Q1FY23